Displaying drugs 15251 - 15275 of 15774 in total
Interleukin-15, human recombinant
Investigational
Odetiglucan
Investigational
Incomplete Freund's adjuvant
Investigational
BI-765063
BI-765063 is a humanized IgG4 monoclonal antibody antagonist of signal regulatory protein α (SIRPα).
Investigational
RO7502175
Investigational
UCPVax
Investigational
GEN-001
Investigational
MRx0518
Investigational
XmAb24306
XmAb24306 is an investigational cancer immunotherapy. It is a heterodimeric interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain.
Investigational
ETBX-021
Investigational
ETBX-061
Investigational
GI-6301
Investigational
SynOV1.1
SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).
Investigational
IO-202
IO-202 is a first-in-class antibody targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) member 4 (LILRB4). It is being investigated in cancers.
Investigational
PF-04856884
PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor. It is under investigation in clinical trial NCT01441414 (PF-04856884 (CVX-060) in Combination With Axitinib in Patients With Previously Treated Metastatic Renal Cell Carcinoma).
Investigational
Immunocytokine NHS-IL12
Investigational
Ixmyelocel-T
Ixmyelocel-T is an expanded, autologous multicellular therapy cultured from bone-marrow mononuclear cells. Developed by Vericel Corporation, it is being investigated for cardiomyopathy.
Investigational
Labafenogene marselecobac
Investigational
Tividenofusp alfa
Tividenofusp alfa, also known as DNL-310, is a brain-penetrant enzyme replacement therapy being investigated for the treatment of Hunter syndrome.
Investigational
RGX-111
RGX-111 is an adeno-associated virus vector AAV9 designed to deliver the α-L-iduronidase (IDUA) gene. Developed by REGENXBIO Inc., it was investigated for the treatment of mucopolysaccharidosis Type I (MPS I).
Investigational
AAV2/8.TBG.hARSB
Investigational
EGT-301
EGT-301 is a gene therapy being investigated for Hunter Syndrome. It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome.
Investigational
OTL-201
OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.
Investigational
Reloxiliase
Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.
Investigational
MRT5201
Investigational
Displaying drugs 15251 - 15275 of 15774 in total